Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Table 4

Treatment response by FcγRIIIA polymorphism p.V158F: non-F-carrier versus F carrier.

	Patients in trial	FcγRIIIA p.158 evaluated	FcγRIIIA p.158 non-F-carrier	FcγRIIIA p.158 F carrier	𝑃
∑ Response to 4 cycles rituximab (PT-LPD1 and PTLD-1 interim staging combined)
Number of patients	87	25	11	14
ORR		17/25	8/11	9/14	0.65
CR		11/25	6/11	5/14	0.35
PR		6/25	2/11	4/14	0.55

ORR denotes overall response rate, CR: complete remission, PR: partial remission, SD: stable disease, and PD: progressive disease. *Missing patients could not be evaluated for response due to early death.